Larimar Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Larimar Therapeutics CEO'su Carole Ben-Maimon, May2020 tarihinde atandı, in görev süresi 4.5 yıldır. in toplam yıllık tazminatı $ 3.14M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.8% maaş ve 82.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler € 661.44K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.3 yıldır.

Anahtar bilgiler

Carole Ben-Maimon

İcra Kurulu Başkanı

US$3.1m

Toplam tazminat

CEO maaş yüzdesi	17.8%
CEO görev süresi	4.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Carole Ben-Maimon'un ücretlendirmesi Larimar Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$65m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$3m	US$560k	-US$37m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$2m	US$528k	-US$35m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$510k	-US$51m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$49m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$5m	US$268k	-US$42m

Tazminat ve Piyasa: Carole 'nin toplam tazminatı ($USD 3.14M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.03M ).

Tazminat ve Kazançlar: Carole şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Carole Ben-Maimon (65 yo)

4.5yrs

Görev süresi

US$3,137,432

Tazminat

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Carole Ben-Maimon	CEO, President & Director	4.5yrs	US$3.14m	0.18% € 661.4k
Michael Celano	Secretary & CFO	4.5yrs	US$1.42m	0.087% € 326.1k
Gopi Shankar	Chief Development Officer	1.8yrs	US$1.43m	0.0078% € 29.3k
John Berman	Vice President of Finance & Administration	1.3yrs	Veri yok	Veri yok
Jennifer Johansson	Vice President of Legal & Compliance	7.9yrs	Veri yok	Veri yok
Russell Clayton	Chief Medical Officer	1.3yrs	Veri yok	Veri yok
Francis Conway	VP & Controller	4.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: ZA71 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Carole Ben-Maimon	CEO, President & Director	4.5yrs	US$3.14m	0.18% € 661.4k
Jonathan Leff	Independent Director	4.5yrs	US$79.96k	Veri yok
Jeffrey Sherman	Independent Director	1.1yrs	US$56.43k	0% € 0
Frank Thomas	Independent Director	10.4yrs	US$86.21k	0.0031% € 11.7k
Thomas Hamilton	Independent Director	4.5yrs	US$77.77k	0.89% € 3.3m
Joseph Truitt	Independent Chairman of the Board	4.5yrs	US$114.96k	0.0043% € 16.1k
Giovanni Manfredi	Member of Scientific Advisory Board	4.1yrs	Veri yok	Veri yok
Mark Payne	Member of Scientific Advisory Board	4.1yrs	Veri yok	Veri yok
Marni Falk	Member of Scientific Advisory Board	4.1yrs	Veri yok	Veri yok
Jill Ostrem	Member of Scientific Advisory Board	2.2yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ZA71 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Larimar Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought €100k worth of stock

High number of new and inexperienced directors

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

New major risk - Revenue and earnings growth

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought €100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Independent Director recently bought €419k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

New 90-day low: €15.00

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

New 90-day high: €18.90

New 90-day high: €18.50

New 90-day high: €15.42

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high - €13.82

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş